Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension

NCT00219024 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
June 30, 2005
Enrollment
2,775 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension